PRESS RELEASE — Gameto, a biotechnology start-up solving the problem of accelerated ovarian aging to change the trajectory of women’s health and equality, announced that it has raised a $20 million in Series A funding.
With some of the initial research conducted at the George Church lab at Harvard Medical School, Gameto has achieved ground-breaking results in creating the first human reprogrammed cells of the ovary (granulosa cells & oocytes precursors) to solve the problem of accelerated ovarian aging, which occurs up to five times faster than any organ in the body.
The round was led by Future Ventures, with participation from Bold Capital Partners, Lux Capital, Plum Alley, TA Ventures, Overwater Ventures and Robert Nelsen and Anne Wojcicki. Gameto also raised $3 million in Seed funding in March 2020 from a range of notable investors including Jack Abraham, SALT Fund, FJ Labs, Dan Rose and Brian Armstrong.
Gameto is building a platform for ovarian therapeutics to initially address menopause and improve assisted fertility with three sequenced programs:
- Fertilo – To improve assisted fertility and with the mission to eliminate infertility over time for all women.
- Deovo – To initiate drug discovery and a computational platform for ovarian aging.
- Ameno – Aiming to make the medical burden of menopause optional.
Based on the rapid aging nature of ovaries, they are an excellent model to study human aging. Gameto wants to synchronize the pace of ovarian aging to the rate of aging in other organs such as the liver, brain, or skin. When ovaries are termed “geriatric” by many traditional medical criteria, the rest of the body is certainly not and this has contributed to the societal and demographic issues we are facing today. Considering human healthspan and lifespan have increased significantly, Gameto believes this biological phenomenon is no longer fit for purpose and is a problem worth solving. Gameto sees the potential to expand its platform to the entire aging market.
“Ovaries age five times faster than other organs, resulting in infertility, early menopause and increased years of poor health for women. We want to change the narrative of female reproductive longevity and address the root causes of sex/gender inequality in our society.” said Dr. Dina Radenkovic, CEO of Gameto.
Dina is a medical doctor, originally from Serbia, trained in the United Kingdom and United States. She worked in the aging field at the Buck Institute in California, was a co-founder and Chief Science Officer of longevity clinic Hooke London and is a Partner at SALT. Gameto also counts Martin Varsavsky as Chairman, Martin is an entrepreneur and among others is the founder of Prelude Fertility, the largest proprietary network of fertility clinics in the USA, and Overture Life, a company working to automate the embryology lab. Gameto is also a part of The Biolabs@NYULangone program.
The Series A funding was led by venture-capital firm Future Ventures. Founded by Steve Jurvetson and Maryanna Saenko, Future Ventures focuses on early-stage disruptive technologies to help trailblazing entrepreneurs develop and commercialize unique ideas that have the potential to reinvent industries.
Based in New York and Boston, Gameto is a biotechnology company translating the impact of ovarian aging to develop solutions to improve fertility and stop the impact of menopause on female health. Gameto brings together an experienced scientific management team with vision and passion to develop groundbreaking platforms for women’s health. Gameto is led by physician turned entrepreneur, Dina Radenkovic, as CEO and serial entrepreneur and a leader in the fertility space, Martin Varsavsky, as Chairman. For more information, go to www.gametogen.com or contact email@example.com.